Therapeutic Asset Ratings
132 results matching 1 filter
128,736 assets · 8,674 sponsors · 3,127 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cromoglycate
schizophrenia
Vishwajit Nimgaonkar, MD PhD
P1/2
CC
(41)
Midomafetamine
schizophrenia
Anya Bershad, MD, PhD
P1/2
CC
(41)
Ocrevus
schizophrenia
The Methodist Hospital Research Institute
P1/2
CC
(41)
mk-5720
schizophrenia
Merck Sharp & Dohme LLC
P1
CC
(40)
QUINIDINE MONO-D-GLUCONATE
schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
P1
CC
(40)
VHX-896
schizophrenia
Vanda Pharmaceuticals
P1
CC
(40)
Zagociguat
schizophrenia
Tisento Therapeutics
P1
CC
(40)
18F-AZAN
schizophrenia
Washington University School of Medicine
P1
C
(37)
ASEM
schizophrenia
Washington University School of Medicine
P1
C
(37)
Delta-9-Thc
schizophrenia
Yale University
P1
C
(37)
Depakine
Schizophrenia
Rakitzi, Stavroula
P1
C
(37)
hs-10509
schizophrenia
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
LIPOPOLYSACCHARIDE
schizophrenia
University of Maryland, Baltimore
P1
C
(37)
Tavor
Schizophrenia
Rakitzi, Stavroula
P1
C
(37)
Tpn-672
schizophrenia
Jiangsu Kanion Pharmaceutical Co., Ltd
P1
C
(37)
Ucb-J
schizophrenia
Davidzon, Guido, M.D.
P1
C
(37)
URB-597
schizophrenia
Central Institute of Mental Health, Mannheim
P1
C
(37)
vv119
schizophrenia
Vigonvita Life Sciences
P1
C
(37)
Riluzole
schizophrenia
King's College London
Early P1
C
(37)
SYNTHETIC LEVOTHYROXINE
schizophrenia
Peking University
Early P1
C
(34)
Aticaprant
schizophrenia
Janssen Research & Development, LLC
P1
D
(30)
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
schizophrenia
Medipol University
N/A
D
(28)
Maltodextrin
schizophrenia
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N/A
D
(28)
METARAMINOL
Schizophrenia
Hôpital le Vinatier
N/A
D
(28)
Midodrine
Schizophrenia
Hôpital le Vinatier
N/A
D
(28)
Showing 101 to 125 of 132 assets
Previous
Page 5 of 6
Next
